Director Daniel Newman Mendelson filed a Form 4 with the SEC on November 9, 2026, disclosing the acquisition of options to purchase common stock of Champions Oncology, Inc. (NASDAQ:CSBR), with the earliest transaction date of November 5, 2026.

Key Highlights

  • Reporting person: Daniel Newman Mendelson, identified as a Director of Champions Oncology, Inc.
  • Security acquired: Options to purchase 20,291 shares of Common Stock, acquired via transaction code A (acquired).
  • Exercise price: $4.76 per share, with an expiration date of November 5, 2036.
  • Beneficial ownership following transaction: 20,291 derivative securities beneficially owned, held directly.
  • Vesting schedule: Options vest over a twelve-month period, with vesting dates on November 5, 2026, February 5, 2027, May 5, 2027, and August 5, 2027.
  • Transaction date: November 5, 2026, as stated in the filing.

Champions Oncology Director Mendelson Acquires Stock Options Vesting Over Twelve Months

According to the Form 4 filed on November 9, 2026, Daniel Newman Mendelson, a Director at Champions Oncology, Inc. (NASDAQ:CSBR), acquired options to purchase 20,291 shares of Common Stock on November 5, 2026. The options carry an exercise price of $4.76 per share and are set to expire on November 5, 2036, the filing disclosed.

The filing reports no non-derivative securities transactions in Table I. All activity was recorded in Table II covering derivative securities. Following the reported transaction, Mendelson beneficially owns 20,291 derivative securities directly, according to the filing. No deemed execution date was listed for the transaction.

The filing's explanation of responses states: "The options vest and are exercisable over a twelve month period, with vesting to occur on November 5, 2026, February 5, 2027, May 5, 2027 and August 5, 2027, respectively." The filing was signed by Daniel Mendelson and dated November 9, 2026. No indication was provided that the transaction was made pursuant to a Rule 10b5-1(c) plan, as the corresponding checkbox was not checked.

What Was Disclosed

Champions Oncology Director Daniel Newman Mendelson disclosed the acquisition of options to purchase 20,291 shares of Common Stock at $4.76 per share, expiring November 5, 2036, with vesting occurring across four dates over twelve months beginning November 5, 2026.